Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: Is this a cost-effective strategy?

European Journal of Preventive Cardiology

Volumn 19, Issue 3, 2012, Pages 474-483

  Ara, R ^a   Pandor, A ^a   Stevens, J ^a   Rafia, R ^a   Ward, S E ^a   Rees, A ^a   Durrington, P N ^b   Reynolds, T M ^c   Wierzbicki, A S ^d   Stevenson, M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c QUEEN S HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Acute coronary syndrome; cost effectiveness; economic evaluation; statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; CHOLESTEROL BLOOD LEVEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; EXPIRATION DATE; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; PATENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

BAYES THEOREM; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MARKOV CHAINS; MEDICATION ADHERENCE; MODELS, ECONOMIC; PYRIMIDINES; PYRROLES; QUALITY INDICATORS, HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; SIMVASTATIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865530645     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711406616     Document Type: Article

References (35)

1. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007 ; 11 (14). 1-160, iii-iv
2. Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother. 2008 ; 9 (12). 1-16
3. Afilalo J, Majdan AA, Eisenberg MJ, Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007 ; 93 (8). 914-921 (Pubitemid 47122038)
4. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 ; 48 (3). 438-445 (Pubitemid 44109954)
5. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Clinical Guideline 67. London: NICE ; 2008 :
6. Department of Health. Better Care Better Value. http://www.institute.nhs. uk/quality-and-value/high-volume-care/better-care-better-value-indicators.html (consulted September 2007).
7. Moon JCB. Switching statins. BMJ. 2006 ; 332 (7554). 1344-1345
8. National Audit Office. Prescribing costs in primary care.http://www/nao. org.uk/publications/0607/prescribing-costs-in-primary-c.aspx. Report by the Controller and Auditor General. HC454 session 2006-2007 18 May 2007-2008 (consulted December 2007).
9. Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet. 2007 ; 369 (9555). 27-27
10. Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin on behalf of the IDEAL Trial Investigators. Eur Heart J. 2007 ; 28 (12). 1448-1453 (Pubitemid 47343816)
11. Lindgren P, Bengt J. From 4 S to IDEAL: the health economics of the statin trials. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 38-143
12. Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high dose lipid-lowering therapy to avoid cardiac events-a systematic review and economic evaluation. Health Technol Assess. 2009 ; 13 ( 34 ):
13. Guide to the methods of technology appraisal. London: NICE ; 2008 :
14. Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008 ; 30 (8). 1508-1523
15. Sonnenberg F, Beck J. Markov models in medical decision making:A practical guide,Med Decis Making. 1993 ; 13 (4). 322-328
16. British Heart Foundation. Statistics database, BHF 2004. http://www.heartstats.org/ (consulted September 2007-2009).
17. Gray D, Hampton JR. Twenty years' experience of myocardial infarction: the value of a heart attack register. Nottingham Heart Attack Register. Br J Clin Pract. 1993 ; 47 (6). 292-295 (Pubitemid 23355322)
18. Fox K, Poole-Wilson P, Clayton T, Henderson R, Shaw T, Wheatley D. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005 ; 366 (9489). 914-920 (Pubitemid 41265665)
19. Henderson R, Pocock SJ, Clayton A. Seven-year outcome in the RITA2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2008 ; 42 (7). 1161-1170
20. Wolfe C, Rudd A, Howard R, Coshall C. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002 ; 72: 211-216
21. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure and extensibility. Statistics Computing. 2000 ; 10 (4). 325-337
22. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
23. British National Formulary. 55 th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008. London: British Medical Association and Royal Pharmaceutical Society of Great Britain ; 2008 :
24. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998 ; 316 (7133). 736-741 (Pubitemid 28121072)
25. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007 ; 154 (5). 815-823
26. Link E, Parish S, Armitage J. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008 ; 359 (8). 789-799
27. Howell N. Compliance with statins in primary care. Pharmaceut J. 2004 ; 272 (7281). 23-26 (Pubitemid 38196385)
28. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2002 ; 88 (2). 203-206 (Pubitemid 34787787)
29. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000 ; 17 (5). 479-500 (Pubitemid 30398806)
30. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head to head randomized controlled trials. Am J Cardiol. 2008 ; 102 (12). 1654-1662
31. Crouse JR, Raichlen JS, Riley WA. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 ; 297: 1344-1353 (Pubitemid 46513235)
32. Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207
33. Goodacre S, Nicholl J, Dixon S, Cross E. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004 ; 328 (7434). 254-257 (Pubitemid 38168133)
34. Serruys P, Unger F, Sousa J. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001 ; 344 (15). 1117-1124 (Pubitemid 32285232)
35. Pickard A, Johnson J, Feeny D. Responsiveness of a generic health-related quality of life measures in stroke. Qual Life Res. 2005 ; 14 (1). 207-219 (Pubitemid 40249095)